CH672796A5 - - Google Patents

Download PDF

Info

Publication number: CH672796A5
Authority: CH; Switzerland
Prior art keywords: hybrid; monoclonal antibody; hybridoma; antibody; polydome
Prior art date: 1982-04-12

Application number

CH6700/83A

Other languages

German (de)

English (en)

Inventor

Joanne Martinis

Richard M Bartholomew

Gary S David

Thomas H Adams

James M Frincke

Original Assignee

Hybritech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1982-04-12

Filing date

1983-04-12

Publication date

1989-12-29

1983-04-12 Application filed by Hybritech Inc filed Critical Hybritech Inc

1989-12-29 Publication of CH672796A5 publication Critical patent/CH672796A5/de

Links

210000004408 hybridoma Anatomy 0.000 claims description 114
239000000427 antigen Substances 0.000 claims description 97
102000036639 antigens Human genes 0.000 claims description 97
108091007433 antigens Proteins 0.000 claims description 97
210000004027 cell Anatomy 0.000 claims description 83
238000000034 method Methods 0.000 claims description 83
102000004190 Enzymes Human genes 0.000 claims description 46
108090000790 Enzymes Proteins 0.000 claims description 46
230000009977 dual effect Effects 0.000 claims description 38
230000004927 fusion Effects 0.000 claims description 29
LPMXVESGRSUGHW-UHFFFAOYSA-N Acolongiflorosid K Natural products OC1C(O)C(O)C(C)OC1OC1CC2(O)CCC3C4(O)CCC(C=5COC(=O)C=5)C4(C)CC(O)C3C2(CO)C(O)C1 LPMXVESGRSUGHW-UHFFFAOYSA-N 0.000 claims description 28
LPMXVESGRSUGHW-GHYGWZAOSA-N Ouabain Natural products O([C@@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1)[C@H]1C[C@@H](O)[C@@]2(CO)[C@@](O)(C1)CC[C@H]1[C@]3(O)[C@@](C)([C@H](C4=CC(=O)OC4)CC3)C[C@@H](O)[C@H]21 LPMXVESGRSUGHW-GHYGWZAOSA-N 0.000 claims description 28
244000166550 Strophanthus gratus Species 0.000 claims description 28
LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 claims description 28
229960003343 ouabain Drugs 0.000 claims description 28
210000001519 tissue Anatomy 0.000 claims description 19
WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims description 18
210000003719 b-lymphocyte Anatomy 0.000 claims description 17
238000004519 manufacturing process Methods 0.000 claims description 17
239000000126 substance Substances 0.000 claims description 17
239000003795 chemical substances by application Substances 0.000 claims description 16
239000003112 inhibitor Substances 0.000 claims description 15
230000000890 antigenic effect Effects 0.000 claims description 14
230000005764 inhibitory process Effects 0.000 claims description 13
231100000518 lethal Toxicity 0.000 claims description 10
230000001665 lethal effect Effects 0.000 claims description 10
LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 claims description 9
229960005508 8-azaguanine Drugs 0.000 claims description 9
239000000203 mixture Substances 0.000 claims description 9
230000005855 radiation Effects 0.000 claims description 9
229960003087 tioguanine Drugs 0.000 claims description 9
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims description 8
230000002427 irreversible effect Effects 0.000 claims description 8
230000035945 sensitivity Effects 0.000 claims description 8
206010028980 Neoplasm Diseases 0.000 claims description 7
230000002068 genetic effect Effects 0.000 claims description 7
239000002738 chelating agent Substances 0.000 claims description 6
238000003745 diagnosis Methods 0.000 claims description 6
241000894007 species Species 0.000 claims description 6
210000004989 spleen cell Anatomy 0.000 claims description 6
238000012258 culturing Methods 0.000 claims description 5
230000002503 metabolic effect Effects 0.000 claims description 5
239000003053 toxin Substances 0.000 claims description 5
231100000765 toxin Toxicity 0.000 claims description 5
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims description 4
XEQLGWAGMYUVTR-UHFFFAOYSA-N O=C1NC=NC2=C1NC=N2.C1=CN=C2C(=O)NC(NN)=NC2=N1 Chemical compound O=C1NC=NC2=C1NC=N2.C1=CN=C2C(=O)NC(NN)=NC2=N1 XEQLGWAGMYUVTR-UHFFFAOYSA-N 0.000 claims description 4
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims description 4
229940104230 thymidine Drugs 0.000 claims description 4
AGNGYMCLFWQVGX-AGFFZDDWSA-N (e)-1-[(2s)-2-amino-2-carboxyethoxy]-2-diazonioethenolate Chemical group OC(=O)[C@@H](N)CO\C([O-])=C\[N+]#N AGNGYMCLFWQVGX-AGFFZDDWSA-N 0.000 claims description 3
MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical compound NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 claims description 3
229950011321 azaserine Drugs 0.000 claims description 3
108010039491 Ricin Proteins 0.000 claims description 2
150000005018 aminopurines Chemical class 0.000 claims 1
239000000480 calcium channel blocker Substances 0.000 claims 1
229940088598 enzyme Drugs 0.000 description 40
239000002609 medium Substances 0.000 description 35
238000012360 testing method Methods 0.000 description 24
239000000523 sample Substances 0.000 description 21
206010003445 Ascites Diseases 0.000 description 17
239000011324 bead Substances 0.000 description 15
238000006243 chemical reaction Methods 0.000 description 12
229940097325 prolactin Drugs 0.000 description 12
239000000758 substrate Substances 0.000 description 12
102000003946 Prolactin Human genes 0.000 description 11
108010057464 Prolactin Proteins 0.000 description 11
230000027455 binding Effects 0.000 description 11
210000002966 serum Anatomy 0.000 description 11
102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 10
108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 10
229940079593 drug Drugs 0.000 description 10
239000003814 drug Substances 0.000 description 10
230000008569 process Effects 0.000 description 9
238000011534 incubation Methods 0.000 description 8
229930193140 Neomycin Natural products 0.000 description 7
206010035226 Plasma cell myeloma Diseases 0.000 description 7
230000008859 change Effects 0.000 description 7
238000001514 detection method Methods 0.000 description 7
238000003018 immunoassay Methods 0.000 description 7
201000000050 myeloid neoplasm Diseases 0.000 description 7
229960004927 neomycin Drugs 0.000 description 7
108090000623 proteins and genes Proteins 0.000 description 7
241000699666 Mus <mouse, genus> Species 0.000 description 6
230000001263 anti-prolactin effect Effects 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
238000000338 in vitro Methods 0.000 description 6
239000000047 product Substances 0.000 description 6
239000006228 supernatant Substances 0.000 description 6
102000005548 Hexokinase Human genes 0.000 description 5
108700040460 Hexokinases Proteins 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
239000002202 Polyethylene glycol Substances 0.000 description 5
102000006601 Thymidine Kinase Human genes 0.000 description 5
108020004440 Thymidine kinase Proteins 0.000 description 5
230000008901 benefit Effects 0.000 description 5
150000001875 compounds Chemical class 0.000 description 5
238000004925 denaturation Methods 0.000 description 5
230000036425 denaturation Effects 0.000 description 5
239000001963 growth medium Substances 0.000 description 5
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 5
230000002163 immunogen Effects 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 5
BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 5
229920001223 polyethylene glycol Polymers 0.000 description 5
239000013641 positive control Substances 0.000 description 5
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 4
XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 4
102100031126 6-phosphogluconolactonase Human genes 0.000 description 4
108010029731 6-phosphogluconolactonase Proteins 0.000 description 4
NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 4
VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 4
108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 4
230000001588 bifunctional effect Effects 0.000 description 4
230000000295 complement effect Effects 0.000 description 4
239000013642 negative control Substances 0.000 description 4
ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 3
102000002260 Alkaline Phosphatase Human genes 0.000 description 3
108020004774 Alkaline Phosphatase Proteins 0.000 description 3
DJHGAFSJWGLOIV-UHFFFAOYSA-N Arsenic acid Chemical compound O[As](O)(O)=O DJHGAFSJWGLOIV-UHFFFAOYSA-N 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
229910019142 PO4 Inorganic materials 0.000 description 3
CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
229940000488 arsenic acid Drugs 0.000 description 3
229940064790 dilantin Drugs 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
238000006911 enzymatic reaction Methods 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
238000000760 immunoelectrophoresis Methods 0.000 description 3
238000009169 immunotherapy Methods 0.000 description 3
239000010452 phosphate Substances 0.000 description 3
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 3
238000012216 screening Methods 0.000 description 3
239000007790 solid phase Substances 0.000 description 3
210000000130 stem cell Anatomy 0.000 description 3
239000013598 vector Substances 0.000 description 3
XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 2
102000013563 Acid Phosphatase Human genes 0.000 description 2
108010051457 Acid Phosphatase Proteins 0.000 description 2
229930024421 Adenine Natural products 0.000 description 2
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 2
DJHGAFSJWGLOIV-UHFFFAOYSA-K Arsenate3- Chemical compound [O-][As]([O-])([O-])=O DJHGAFSJWGLOIV-UHFFFAOYSA-K 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
102000008857 Ferritin Human genes 0.000 description 2
108050000784 Ferritin Proteins 0.000 description 2
238000008416 Ferritin Methods 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
239000004793 Polystyrene Substances 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
229960000643 adenine Drugs 0.000 description 2
229940000489 arsenate Drugs 0.000 description 2
230000007910 cell fusion Effects 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
230000006378 damage Effects 0.000 description 2
239000000539 dimer Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
239000000499 gel Substances 0.000 description 2
239000008103 glucose Substances 0.000 description 2
230000028993 immune response Effects 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
238000004255 ion exchange chromatography Methods 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
239000000463 material Substances 0.000 description 2
230000009871 nonspecific binding Effects 0.000 description 2
239000012071 phase Substances 0.000 description 2
229920002223 polystyrene Polymers 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
235000018102 proteins Nutrition 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
238000010791 quenching Methods 0.000 description 2
230000000171 quenching effect Effects 0.000 description 2
239000000700 radioactive tracer Substances 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
238000010187 selection method Methods 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
108091006112 ATPases Proteins 0.000 description 1
102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
238000009007 Diagnostic Kit Methods 0.000 description 1
102000016607 Diphtheria Toxin Human genes 0.000 description 1
108010053187 Diphtheria Toxin Proteins 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
108700004714 Gelonium multiflorum GEL Proteins 0.000 description 1
108010015776 Glucose oxidase Proteins 0.000 description 1
239000004366 Glucose oxidase Substances 0.000 description 1
206010019695 Hepatic neoplasm Diseases 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
241000283977 Oryctolagus Species 0.000 description 1
108030004873 Phosphoribosylformylglycinamidine synthases Proteins 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
101710119110 Prolactin-1 Proteins 0.000 description 1
238000010266 Sephadex chromatography Methods 0.000 description 1
241000191967 Staphylococcus aureus Species 0.000 description 1
102100037409 Sushi, von Willebrand factor type A, EGF and pentraxin domain-containing protein 1 Human genes 0.000 description 1
101710116672 Sushi, von Willebrand factor type A, EGF and pentraxin domain-containing protein 1 Proteins 0.000 description 1
101150003725 TK gene Proteins 0.000 description 1
241000700605 Viruses Species 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
238000001261 affinity purification Methods 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000013459 approach Methods 0.000 description 1
210000003567 ascitic fluid Anatomy 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
238000006555 catalytic reaction Methods 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
238000012832 cell culture technique Methods 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000010367 cloning Methods 0.000 description 1
239000005515 coenzyme Substances 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000001268 conjugating effect Effects 0.000 description 1
238000010276 construction Methods 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
238000010924 continuous production Methods 0.000 description 1
239000013068 control sample Substances 0.000 description 1
239000007822 coupling agent Substances 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
239000003431 cross linking reagent Substances 0.000 description 1
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
230000034994 death Effects 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
238000007865 diluting Methods 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
229910000397 disodium phosphate Inorganic materials 0.000 description 1
235000019800 disodium phosphate Nutrition 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000012634 fragment Substances 0.000 description 1
238000007499 fusion processing Methods 0.000 description 1
229940116332 glucose oxidase Drugs 0.000 description 1
235000019420 glucose oxidase Nutrition 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
230000012010 growth Effects 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
210000004754 hybrid cell Anatomy 0.000 description 1
PPTXFSQSISUDAU-UHFFFAOYSA-M hydrogen sulfate;2-methyl-4-[(2-methylphenyl)diazenyl]benzenediazonium Chemical compound OS([O-])(=O)=O.CC1=CC=CC=C1N=NC1=CC=C([N+]#N)C(C)=C1 PPTXFSQSISUDAU-UHFFFAOYSA-M 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000003053 immunization Effects 0.000 description 1
230000000984 immunochemical effect Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
238000013198 immunometric assay Methods 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
238000005304 joining Methods 0.000 description 1
238000002372 labelling Methods 0.000 description 1
231100000636 lethal dose Toxicity 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
208000014018 liver neoplasm Diseases 0.000 description 1
230000004807 localization Effects 0.000 description 1
238000004020 luminiscence type Methods 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
230000035772 mutation Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
239000011824 nuclear material Substances 0.000 description 1
238000011580 nude mouse model Methods 0.000 description 1
229940092253 ovalbumin Drugs 0.000 description 1
230000020477 pH reduction Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
WFLQAMUOBIONDG-UHFFFAOYSA-N phenoxyarsonic acid Chemical compound O[As](O)(=O)OC1=CC=CC=C1 WFLQAMUOBIONDG-UHFFFAOYSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
WGJJROVFWIXTPA-OALUTQOASA-N prostanoic acid Chemical compound CCCCCCCC[C@H]1CCC[C@@H]1CCCCCCC(O)=O WGJJROVFWIXTPA-OALUTQOASA-N 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
238000004153 renaturation Methods 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000006152 selective media Substances 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical class CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 1
238000001890 transfection Methods 0.000 description 1
239000013638 trimer Substances 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
- A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo

Landscapes

Health & Medical Sciences (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Biophysics (AREA)
Epidemiology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Physics & Mathematics (AREA)
Optics & Photonics (AREA)
Pharmacology & Pharmacy (AREA)
Molecular Biology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

CH6700/83A 1982-04-12 1983-04-12 CH672796A5 (it)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US36778482A	1982-04-12	1982-04-12

Publications (1)

Publication Number	Publication Date
CH672796A5 true CH672796A5 (it)	1989-12-29

Family

ID=23448582

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CH6700/83A CH672796A5 (it)	1982-04-12	1983-04-12

Country Status (11)

Country	Link
EP (1)	EP0105360A4 (it)
JP (2)	JPH0753119B2 (it)
AT (1)	AT394577B (it)
AU (1)	AU550486B2 (it)
CA (1)	CA1213229A (it)
CH (1)	CH672796A5 (it)
ES (7)	ES521370A0 (it)
FI (1)	FI834529A0 (it)
GB (4)	GB2128631B (it)
IT (1)	IT1219778B (it)
WO (1)	WO1983003679A1 (it)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3177776B2 (ja) *	1988-09-27	2001-06-18	武田薬品工業株式会社	ハイブリッドモノクローナル抗体，抗体産生ポリドーマおよび抗体含有薬剤
US5292668A (en) *	1981-12-21	1994-03-08	Boston Biomedical Research Institute, Inc.	Bispecific antibody determinants
IL70686A (en) *	1983-01-20	1988-07-31	Suntory Ltd	Mutant tumor cell lines for use in the preparation of hybridomas and the hybridomas obtained therefrom
GB2148299B (en) *	1983-09-01	1988-01-06	Hybritech Inc	Antibody compositions of therapeutic agents having an extended serum half-life
EP0467416A1 (en) *	1983-09-01	1992-01-22	Hybritech Incorporated	Antibody compositions of therapeutic agents having an extended serum half-life
AU595159B2 (en) *	1984-04-23	1990-03-29	Boston Biomedical Research Institute Incorporated	Bispecific antibody determinants
NL8501219A (nl) *	1985-04-29	1986-11-17	Stichting Vrienden Van De Stic	Immunologisch complex, de bereiding en toepassing daarvan.
EP0241907A3 (en)	1986-04-14	1989-09-13	The General Hospital Corporation	Heterobifunctional antibodies and method of use
US5453269A (en) *	1986-04-14	1995-09-26	The General Hospital Corporation	Heterobifunctional antibodies having dual specificity for fibrin and thrombolylic agents and methods of use
FR2604092B1 (fr) *	1986-09-19	1990-04-13	Immunotech Sa	Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo
GB8626413D0 (en) *	1986-11-05	1986-12-03	Gilliland L K	Antibodies
GB8626412D0 (en) *	1986-11-05	1986-12-03	Clark M R	Antibodies
US5053226A (en) *	1987-07-15	1991-10-01	Board Of Regents, The University Of Texas System	Monoclonal antibodies binding platinum complexes
JP2755395B2 (ja) *	1987-09-23	1998-05-20	ブリストル―マイアーズスクイブコムパニー	Ｈｉｖ感染細胞に殺作用する抗体異種結合体
GB2218100A (en) *	1988-03-02	1989-11-08	Erling Sundrehagen	Conjugates for the detection and/or quantification of antigenic substances in body fluids
US4892824A (en) *	1988-03-15	1990-01-09	Synbiotics Corporation	Fast track method for producing monoclonal bi-specific immunoglobulins
US5582862A (en) *	1988-04-04	1996-12-10	General Hospital Corporation	Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
US5372812A (en) *	1988-04-04	1994-12-13	The General Hospital Corporation	Composition and method for acceleration of clot lysis
JPH02196799A (ja) *	1988-04-08	1990-08-03	Agency Of Ind Science & Technol	抗ヒト癌蛋白複合体
US5851527A (en) *	1988-04-18	1998-12-22	Immunomedics, Inc.	Method for antibody targeting of therapeutic agents
IT1235349B (it) *	1988-12-23	1992-06-30	Biodata Spa	Saggio immunologico per determinazioni in fase omogenea
US5217713A (en) *	1988-12-27	1993-06-08	Takeda Chemical Industries, Ltd.	Cytotoxic bispecific monoclonal antibody, its production and use
CA2006408A1 (en) *	1988-12-27	1990-06-27	Susumu Iwasa	Bispecific monoclonal antibody, its production and use
WO1990012109A1 (en) *	1989-03-30	1990-10-18	Board Of Regents, The University Of Texas System	Monoclonal antibodies binding platinum complexes
FR2652004B1 (fr) *	1989-09-21	1994-10-28	Immunotech Partners	Nouveaux derives hydrophiles, application au diagnostic et a la therapeutique, kits diagnostiques ou therapeutiques et reactifs immunologiques.
DE69130561T2 (de) *	1990-02-16	1999-06-24	Boston Biomedical Research Institute, Inc., Boston, Mass.	Hybride Reagenzien mit der Fähigkeit, Moleküle selektiv in Zellen freizusetzen
TW212184B (it) *	1990-04-02	1993-09-01	Takeda Pharm Industry Co Ltd
US5573920A (en) *	1991-04-26	1996-11-12	Surface Active Limited	Antibodies, and methods for their use
GB9316369D0 (en) *	1993-08-06	1993-09-22	Surface Active Ltd	Diagnostic method
US5541110A (en)	1994-05-17	1996-07-30	Bristol-Myers Squibb	Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
GB9421468D0 (en) *	1994-10-18	1994-12-07	Surface Active Ltd	Biosensor
EP0937146A2 (en) *	1996-09-20	1999-08-25	The General Hospital Corporation	Composition and method for enhancing fibrinolysis using antibodies to alpha-2-antiplasmin
US20020132274A1 (en)	2001-01-17	2002-09-19	Nevalainen Marja T.	Diagnostic and monitorings methods for cancer
US7659241B2 (en)	2002-07-31	2010-02-09	Seattle Genetics, Inc.	Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
US7498298B2 (en)	2003-11-06	2009-03-03	Seattle Genetics, Inc.	Monomethylvaline compounds capable of conjugation to ligands
US7932242B2 (en)	2004-03-16	2011-04-26	Temple University - Of The Commonwealth System Of Higher Education	Substituted phenoxy-and phenylthio-derivatives for treating proliferative disorders
JP2008519863A (ja)	2004-11-12	2008-06-12	シアトルジェネティクスインコーポレイティッド	Ｎ末端にアミノ安息香酸単位を有するオーリスタチン
EP2511299A1 (en)	2005-04-19	2012-10-17	Seattle Genetics, Inc.	Humanized anti-CD70 binding agents and uses thereof
EP4026840A1 (en)	2005-07-18	2022-07-13	Seagen Inc.	Beta-glucuronide-linker drug conjugates
EP2609932B1 (en)	2006-12-01	2022-02-02	Seagen Inc.	Variant target binding agents and uses thereof
ZA200904482B (en)	2007-01-22	2010-09-29	Genentech Inc	Polyelectrolyte precipitation and purification of antibodies
AU2009242453B2 (en)	2008-05-02	2014-12-04	Seagen Inc.	Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
WO2011133658A1 (en)	2010-04-22	2011-10-27	Boston Medical Center Corporation	Compositions and methods for targeting and delivering therapeutics into cells
WO2014089177A2 (en)	2012-12-04	2014-06-12	Massachusetts Institute Of Technology	Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
MY174813A (en)	2013-03-15	2020-05-16	Zymeworks Inc	Cytotoxic and anti-mitotic compounds, and methods of using the same
JP6473418B2 (ja)	2013-10-10	2019-02-20	幸成加藤	抗ポドプラニン抗体
CN106255513B (zh)	2013-12-27	2022-01-14	酵活有限公司	用于药物偶联物的含磺酰胺连接***
AU2015318556C1 (en)	2014-09-17	2021-01-07	Zymeworks Bc Inc.	Cytotoxic and anti-mitotic compounds, and methods of using the same
US10618935B2 (en)	2015-11-03	2020-04-14	Industrial Technology Research Institute	Antibody-drug conjugate (ADC) and method for forming the same
SG11201807827VA (en)	2016-03-25	2018-10-30	Seattle Genetics Inc	Process for the preparation of pegylated drug-linkers and intermediates thereof
US10918627B2 (en)	2016-05-11	2021-02-16	Massachusetts Institute Of Technology	Convergent and enantioselective total synthesis of Communesin analogs
MX2019010769A (es)	2017-03-24	2019-12-11	Seattle Genetics Inc	Proceso para la preparacion de enlazadores de farmacos de glucuronidos y compuestos intermediarios de los mismos.
US11932650B2 (en)	2017-05-11	2024-03-19	Massachusetts Institute Of Technology	Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en)	2017-10-13	2020-05-05	Massachusetts Institute Of Technology	Diazene directed modular synthesis of compounds with quaternary carbon centers
CA3110096A1 (en)	2018-08-30	2020-03-05	Innovative Cellular Therapeutics CO., LTD.	Chimeric antigen receptor cells for treating solid tumor
US20220409734A1 (en)	2019-05-10	2022-12-29	Yutaka Nishimoto	Antibody drug conjugates
TW202138388A (zh)	2019-12-30	2021-10-16	美商西根公司	以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
US12043654B2 (en)	2020-06-02	2024-07-23	Innovative Cellular Therapeutics Holdings, Ltd.	Anti-GCC antibody and CAR thereof for treating digestive system cancer
WO2022097117A1 (en)	2020-11-09	2022-05-12	Takeda Pharmaceutical Company Ltd.	Antibody drug conjugates
WO2022182415A1 (en)	2021-02-24	2022-09-01	Massachusetts Institute Of Technology	Himastatin derivatives, and processes of preparation thereof, and uses thereof
WO2023278377A1 (en)	2021-06-29	2023-01-05	Seagen Inc.	Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4130634A (en) *	1974-03-15	1978-12-19	University Of Illinois Foundation	Method for detecting and quantifying antigens
US4331647A (en) *	1980-03-03	1982-05-25	Goldenberg Milton David	Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4376110A (en) *	1980-08-04	1983-03-08	Hybritech, Incorporated	Immunometric assays using monoclonal antibodies
US4474893A (en) *	1981-07-01	1984-10-02	The University of Texas System Cancer Center	Recombinant monoclonal antibodies

1983
- 1983-04-11 ES ES521370A patent/ES521370A0/es active Granted
- 1983-04-11 CA CA000425558A patent/CA1213229A/en not_active Expired
- 1983-04-12 WO PCT/US1983/000525 patent/WO1983003679A1/en not_active Application Discontinuation
- 1983-04-12 GB GB08332646A patent/GB2128631B/en not_active Expired
- 1983-04-12 EP EP19830901672 patent/EP0105360A4/en not_active Ceased
- 1983-04-12 IT IT20548/83A patent/IT1219778B/it active
- 1983-04-12 AU AU15559/83A patent/AU550486B2/en not_active Expired
- 1983-04-12 CH CH6700/83A patent/CH672796A5/de not_active IP Right Cessation
- 1983-04-12 AT AT0901883A patent/AT394577B/de not_active IP Right Cessation
- 1983-12-09 FI FI834529A patent/FI834529A0/fi not_active Application Discontinuation
- 1983-12-12 ES ES527963A patent/ES8503441A1/es not_active Expired
1984
- 1984-07-02 ES ES533930A patent/ES8603080A1/es not_active Expired
- 1984-07-02 ES ES533931A patent/ES533931A0/es active Granted
- 1984-10-31 ES ES537257A patent/ES8606655A1/es not_active Expired
- 1984-12-18 ES ES538727A patent/ES8604424A1/es not_active Expired
1985
- 1985-07-16 ES ES545247A patent/ES8607386A1/es not_active Expired
- 1985-12-09 GB GB08530310A patent/GB2167086B/en not_active Expired
- 1985-12-09 GB GB08530308A patent/GB2168998B/en not_active Expired
- 1985-12-09 GB GB08530309A patent/GB2169921B/en not_active Expired
1987
- 1987-01-05 JP JP62000342A patent/JPH0753119B2/ja not_active Expired - Lifetime
1994
- 1994-02-10 JP JP6016728A patent/JP2562002B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
FI834529A (fi)	1983-12-09
CA1213229A (en)	1986-10-28
ATA901883A (de)	1991-10-15
ES527963A0 (es)	1985-02-16
ES8504461A1 (es)	1985-04-16
JPS6312276A (ja)	1988-01-19
GB8530310D0 (en)	1986-01-22
GB2128631A (en)	1984-05-02
ES8607386A1 (es)	1986-05-16
ES8503441A1 (es)	1985-02-16
GB8332646D0 (en)	1984-01-11
GB2169921B (en)	1987-03-04
IT1219778B (it)	1990-05-24
WO1983003679A1 (en)	1983-10-27
ES537257A0 (es)	1986-04-01
GB2168998B (en)	1987-03-04
GB2167086B (en)	1987-03-04
ES545247A0 (es)	1986-05-16
FI834529A0 (fi)	1983-12-09
JPH0753600A (ja)	1995-02-28
AU550486B2 (en)	1986-03-20
GB8530309D0 (en)	1986-01-22
GB2169921A (en)	1986-07-23
ES521370A0 (es)	1985-04-16
ES538727A0 (es)	1986-02-01
GB8530308D0 (en)	1986-01-22
GB2168998A (en)	1986-07-02
EP0105360A4 (en)	1986-07-08
AU1555983A (en)	1983-11-04
ES8606655A1 (es)	1986-04-01
ES8506091A1 (es)	1985-06-16
AT394577B (de)	1992-05-11
GB2128631B (en)	1987-02-25
GB2167086A (en)	1986-05-21
ES8604424A1 (es)	1986-02-01
JPH0753119B2 (ja)	1995-06-07
IT8320548A0 (it)	1983-04-12
ES533931A0 (es)	1985-06-16
EP0105360A1 (en)	1984-04-18
JP2562002B2 (ja)	1996-12-11
ES533930A0 (es)	1985-12-01
ES8603080A1 (es)	1985-12-01

Legal Events

Date	Code	Title	Description
1993-12-31	PL	Patent ceased

Publication	Publication Date	Title
AT394577B (de)	1992-05-11	Polydom, verfahren zu seiner herstellung und immunodiagnostische verfahren
DE3751432T2 (de)	1996-03-21	Rezeptoren für Immunkomplexe, Verfahren zur ihrer Herstellung und Verfahren zur Prüfung diese benutzend.
DE69214709T2 (de)	1997-02-20	Neue Antikörper und Verfahren zu ihrer Verwendung
DE3854194T2 (de)	1996-03-21	Monoklonale antikörper gegen glykosyliertes albumin, hybride zellinien, die diese antikörper produzieren, sowie deren verwendung.
DE3783928T2 (de)	1993-07-15	Verfahren zur immunoassay.
DE69824178T2 (de)	2005-06-23	Verfahren zur specifischen bestimmung der c-peptide
DE3750389T2 (de)	1994-12-01	Antikörper gegen menschlichen progesteronrezeptor sowie diagnosematerial und -verfahren.
EP0134552B1 (de)	1992-10-28	Monoklonaler Antikörper mit hoher Affinität zum Digoxin
DE3205849C2 (de)	1985-06-27	Reagens zur immunologischen Bestimmung
JPS60228962A (ja)	1985-11-14	複数の抗体を同時に検出する為の方法
EP0449269B1 (de)	1996-05-15	Verfahren zum Nachweis von phosphoryliertes Tyrosin enthaltenden Proteinen
DE69427122T2 (de)	2002-01-03	Kompetitiver immunotest unter verwendung eines bindenden proteins in multiklonaler antikoerperstruktur
EP0547059B1 (de)	1995-10-04	Pankreas-elastase-1-spezifischer antikörper, ein verfahren zu seiner gewinnung und ein testkit der solche antikörper enthält
DE69008178T2 (de)	1994-10-06	Analyse von vitamin b12.
DE4008546C2 (it)	1991-07-04
DE60036452T2 (de)	2008-06-19	Monoklonaler anti-uracil antikörper
DE69110067T2 (de)	1996-02-22	Monoklonale Antikörper gegen nicht-A 1C glykosyliertes Hämoglobin.
DE60318271T2 (de)	2008-12-11	Antikörper gegen allgegenwärtige mitochondriale Kreatinkinase und dessen Verwendung
DE3820556A1 (de)	1989-12-21	Verfahren zur bestimmung von allergenspezifischen antikoerpern in koerperfluessigkeiten
DE3686068T2 (de)	1993-02-11	Verfahren zur bestimmung von menschlicher prolyl-4-hydroxylase durch immunotest.
DE3036184A1 (de)	1981-04-16	Reagenz und verfahren zur bestimmung von human-muskeltyp-aldolase
EP0182888B1 (de)	1991-12-04	Verfahren und reagenz zur differenzierten bestimmung von isoenzymen der alkalischen phosphatase sowie hierzu geeigneter monoklonaler antikörper
JPS59500696A (ja)	1984-04-26	二重特異性を有する抗体、その製造及びその用途
DE4119395C2 (de)	1996-09-12	Monoklonaler Antikörper, der gegen delta-Bilirubin spezifisch ist, seine Verwendung zur Bestimmung von delta-Bilirubin und die entsprechende Antikörperproduzierende Hybridomazellinie
DE68909276T2 (de)	1994-04-07	Monoklonale Antikörper, geeignet für den aus der menschlichen Bauchspeicheldrüse sekretierten Trypsin-Inhibitor, Hybridomen, die diese produzieren und ihre Herstellung und Verwendung.